November 9

9 a.m. – Registration opens

10 – 10:45 a.m. – Opening Keynote: Scott Hamilton, Founder, Scott Hamilton Cares Foundation

“I choose to celebrate life.”
Kicking off LST|CON and grounding us as we explore the value of life science technologies is U.S. Olympic gold mentalist, and cancer survivor, Scott Hamilton. Scott continues to inspire us through his Scott Hamilton CARES initiative which he created to link arms with the cancer community, ask questions, and work to improve cancer treatment.

scott hamilton oval

11 a.m. – Noon – Morning Breakout Sessions

The Value of Life Science Technologies – Advances in the med-tech, bio-tech, pharmaceutical and agricultural industries have produced life-changing innovations and allowed people to live longer and higher quality lives. These advances have also brought savings in medicals costs, including decreased hospital stays and doctor visits.

To increase medical advances, we must create an environment conducive for innovations to thrive and support public policy initiatives that support innovation, investment and great access to care.

saiza oval
Saiza-Jem F. Elayda, PhRMA

Evolving Principles in Technology Transfer – University technology transfer is a cornerstone to developing cures and therapies and bringing new innovative technology to the marketplace. In 2017, the APLU published a new vision for technology transfer offices and the expectations for growth. Top Tennessee technology transfer offices will outline innovative programs for educating entrepreneurs and how industry engagement is critical to the technology transfer process.

chaloner oval  bentley oval 2 magid oval riggs oval

Aaron Chaloner, Baker Donelson (Moderator)
Alan Bentley, Vanderbilt University
Richard Magid, University of Tennessee Research Foundation
Chad Riggs, St. Jude Children’s Research Hospital

12:00 – 12:30 p.m. – Networking Lunch

12:30 – 1:15 p.m. – Disrupting the Information Flow to Deliver Better Care
                      Ed Cantwell, President and CEO, Center for Medical Interoperability

Medical devices and health care systems have been stymied by an inability to exchange patient information with ease, creating a healthcare system that can seem fragmented and inefficient. The Center for Medical Interoperability maintains a firm belief that patient care can be dramatically improved and costs lowered by the integration of medical data from device to device.

ed cantwell oval

1:15 – 2 p.m. – Policy Trends and Considerations

This panel of experts will overview the current impact of state and federal policy initiatives that affect the delivery of life science technologies to the patient.

josh brown oval  seltman oval tom tremble saiza oval

Josh Brown, Pfizer
Paul Seltman, Smith & Nephew
Tom Tremble, AdvaMed
Saiza-Jem F. Elayda, PhRMA

2 – 2:15 p.m. – Life Science Tennessee Announcements and Update

2:30 – 3:30 p.m. – Afternoon Breakout Sessions

SBIR in Tennessee: Lessons Learned from SBIR Recipients –
Sponsored by: Launch Tennessee
Tennessee is rolling out a brand new SBIR/STTR matching program, allowing Tennessee-based innovators an opportunity to make funds go further. There is no better time to be an entrepreneur in Tennessee and this panel of SBIR winners knows why. Join this breakout session to hear details of Launch Tennessee’s Microgrants Program and the new SBIR/STTR Matching Program and dialogue with start-up leaders about the advantages or challenges SBIR recipients face.

  jim stefansic ovalchris p ovalripp oval
Jim Stefansic, Raiven Healthcare (Moderator)
Chris Przybyszewski, U.S. Biologic
Steven Ripp, 490 Biotech

Keeping Life Science Talent in Tennessee – Tennessee boasts some of the nation’s best research universities and institutes. Still, a communication gap remains between academics and industry representatives on Ph.D. preparation. This discussion will focus on the training programs in place at Tennessee universities, what companies look for during hiring practices and how collaboration can increase retention of qualified talent.

ashley brady oval Lindsey Morris oval

Ashley Brady, Vanderbilt University
Lindsey Morris, Axial Healthcare

3:45 – 4:45 p.m. – Closing Keynote: Joel Wood, The Foundation to Eradicate Duchennes

Aggressive Action: The Fight to Eradicate Duchenne
Fighting Duchenne Muscular Dystrophy, the world’s leading lethal childhood genetic disease, with an approach that matches and then exceeds the aggressive nature of the disease, our closing keynote speaker Joel Wood established the Foundation to Eradicate Duchenne Muscular Dystrophy after his son James was diagnosed. Joel will explore the trials and tribulations of raising a child in a time of remarkable developments in health care and how he is fighting successfully for treatments to extend and improve the lives of those affected by Duchenne, and ultimately, a cure for James.

joel wood oval

4:45 – 6 p.m. – Cocktail Reception

November 10

7:30 – 10 a.m. – Life Science Tennessee Venture Forum

Participating companies:

  1. Frontier Diagnostics – Frontier is a leading provider of molecular diagnostics utilizing imaging mass spectrometry, a proprietary technology that can be used by anatomic pathologists to make more objective diagnostic decisions. Frontier is developing their first commercial assay, MelanoMap, for the diagnosis of melanoma. Frontier also provides assay development services and diagnostic trial management to diagnostic laboratories and pharmaceutical companies.
  2. NeuroDyne – NeuroDyne is a medical technology company with 20+ years of experience in neuromodulation that researches and develops new technology for the neurological device industry. They have developed a seizure monitoring device that can be worn at home and enables physicians to capture neurological data outside of hospital setting.
  3. Safe Stamp – SafeStamp implements advanced nanotechnology that helps consumers in emerging markets know that their medicine is authentic and defeat pharmaceutical counterfeiting.
  4. IQuity – IQuity is a life science technology company leveraging machine learning methods to deliver breakthrough RNA diagnostics and analytics. The company’s initial offerings include Isolate tests across neurology, gastroenterology and rheumatology that are based on proprietary algorithms capable of ‘ruling in’ or ‘ruling out’ specific autoimmune diseases.

Venture Forum flier image